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Autosomal-dominant progressive external ophthalmoplegia (adPEO) is a mitochondrial disorder that is characterized by accumulation
of multiple mitochondrial DNA (mtDNA) deletions in postmitotic tissues. The disorder is heterogeneous, with ﬁve known nuclear
disease genes that encode the proteins ANT1, Twinkle, POLG, POLG2, and OPA1. Defects in these proteins affect mtDNAmaintenance,
probably leading to stalled replication forks, consequent mtDNA deletion formation, and progressive respiratory chain deﬁciency. Here
we present a large adPEO family with multiple mtDNA deletions, whose disease was not explained by mutations in any of the known
adPEO loci. We mapped the disease locus in this family to chromosome 8q22.1-q23.3. The critical linkage region contained the RRM2B
gene, which encodes the small subunit of the ribonucleotide reductase p53R2, which has previously been shown to be essential for the
maintenance of mtDNA copy number. Mutation screening of RRM2B revealed a heterozygous nonsense mutation in exon 9 (c.979C/
T [p.R327X]) in all affected individuals that was absent in 380 control chromosomes. The same mutation was found to segregate in
another adPEO family. The mutant mRNA escaped nonsense-mediated decay and resulted in a protein with truncation of 25 highly
conserved C-terminal amino acids essential for the interaction with the ribonucleotide reductase subunit R1. We conclude that domi-
nant-negative or gain-of-function mutations in RRM2B are a cause of multiple mtDNA deletions and adPEO.Autosomal-dominant progressive external ophthalmople-
gia (adPEO) (MIM 157640; 609283; 609286; 610131) is
characterized by multiple mitochondrial DNA deletions
in postmitotic tissues and respiratory-chain-deﬁcient
ragged-red ﬁbers with abnormal mitochondria in the
muscle biopsy.1 Its most common clinical features include
adult-onset weakness of the external eye muscles and exer-
cise intolerance. Additional symptoms are variable and
may include cataracts, hearing loss, sensory axonal
neuropathy, optic atrophy, ataxia, depression, hypogonad-
ism, and Parkinsonism.2–6
adPEO is a genetically heterogeneous disorder. We and
others have previously reported underlying mutations in
ﬁve genes encoding both subunits of DNA polymerase
gamma (POLG [MIM 174763] and POLG2 [MIM 604983]),
the DNA helicase Twinkle (C10ORF2 [MIM 606075]), the
adenine nucleotide translocator ANT1 (SLC25A4 [MIM
103220]), and optic atrophy 1 (OPA1 [MIM 605290]).7–11
POLG and Twinkle are essential parts of the mtDNA repli-
some12 in the mitochondrial nucleoid, whereas ANT1
may affect mtDNAmaintenance by regulating the intrami-
tochondrial adenine pools via its function as the ADP/ATP
translocator in the innermitochondrialmembrane.Defects
in these proteins are believed to disturbmtDNA replication,
thus leading to stalled replication forks and consequently
mtDNA deletion formation.13 In addition to the dominant
trait, recessively inherited conditions caused by mutations
in the same genes have also been described, often resulting290 The American Journal of Human Genetics 85, 290–295, Augustin mtDNA copy-number depletion and/or in a more severe
disease with early onset.14–17 OPA1 participates in mito-
chondrial inner-membrane fusion, and the mechanism by
which its defects cause mtDNA deletions could involve
nucleoid segregation or mtDNA turnover.
Several adPEO families have been identiﬁed in which
mutations in SLC25A4, POLG, POLG2, C10ORF2, or OPA1
are not responsible for the disease phenotype. To identify
the underlying gene in one such family, we recruited
members of a large four-generation North American family
of European origin that has 13 affected individuals and an
autosomal-dominant inheritance pattern (family 1, Fig-
ure 1). The diagnosis was based on the ﬁnding of ophthal-
moparesis and ptosis with the onset of symptoms or signs
late in the second decade or in adult life. Some affected
family members had restricted eye movements without
ptosis. Commonly, patients were unaware of limitations
in eye movements until they were discovered in routine
medical examinations. In addition, some patients experi-
enced easy muscle fatigue with exercise. The patients
who underwent muscle biopsy exhibited cytochrome c
oxidase-deﬁcient skeletal muscle ﬁbers (Figure 2A) and
had multiple mtDNA deletions in muscle (Figure 2B), de-
tected by long-range polymerase chain reaction (PCR) as
described previously.18 mtDNA deletions were not present
in patients’ lymphocytes. Informed consent was obtained
from all participating patients and unaffected family
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Figure 1. The adPEO Pedigrees
The reduced pedigrees of the families show the participating members and their immediate relatives. The members of family 1 whose
genotype data were used in the linkage analyses are marked with an asterisk (*). The individuals marked with a question mark (?) were
not clinically or genetically examined.of the University of Texas Southwestern Medical Center.
We also obtained 190 unrelated anonymous DNA samples
of European origin, which were used as controls.
DNA was extracted from whole blood or muscle biopsy
via standard procedures. A genome-wide scan for linkage
was performed with an Illumina Inﬁnium HumanLink-
age-12 panel containing 6090 SNPs. The genotype data
of nine patients and three unaffected family members
of family 1 (Figure 1) were included in the multipoint
logarithm of the odds (LOD) score analysis, which was
performed with the MERLIN program. The analysis was
conducted assuming an autosomal-dominant mode of
inheritance with full penetrance and no phenocopies. A
disease allele frequency of 0.001 was used in the analysis.
The allele frequency for all markers was assumed to be
equal. The 16 Mb region between SNPs RS874643 and
RS1019603 on chromosome 8 (8q22.1-q23.3) was identi-
ﬁed as the region of signiﬁcant linkage (see Figure S1 avail-
able online). A maximum multipoint LOD score of 3.6
occurred at 17 SNP markers between RS2022922 and
RS3110040. No linkage was found in chromosomes
10q24, 4q35, 15q25, 17q23, or 3q28-q29 where the previ-
ously identiﬁed adPEO disease genes reside (Figure S1).
The positive linkage region comprises 59 known and pre-
dicted genes. One of the genes, RRM2B, has previously been
shown to have a role in the maintenance of mtDNA copy
number19 and was therefore subjected to direct sequencing
as a ﬁrst priority. The genomic structure of RRM2B consists
of nine exons spanning ~35 kb on chromosome 8. The
full-length mRNA is 4955 bp and encodes a 351 aa protein,
p53R2. Primers were designed to amplify all RRM2B exons,The Amerisplice sites, and the ﬂanking sequences (Table S1).
Sequencing of the ampliﬁed fragments was initially per-
formed foroneaffected individual (family1, III:1). Sequence
analysis revealed a nonsense mutation in the last exon of
RRM2B, exon 9: c.979C/T (p.R327X), which changes an
arginine residue to a premature termination codon, predict-
ing a proteinwith truncation of the last 25 amino acids (Fig-
ure 3B). This mutation segregated with the disease pheno-
type in the examined family members and was not found
in 380 control chromosomes of European origin.
We also collected DNA samples of patients from six PEO
families with an unidentiﬁed gene defect and screened
those for mutations in RRM2B by direct sequencing. We
identiﬁed the same c.979C/T mutation in patients of
an adPEO family of Hungarian origin (family 2, Figure 1).
Patient III:2 in this family was a 40-year-old male who
had suffered from exercise intolerance and bilateral ptosis
since his twenties. Neurological investigation revealed
external ophthalmoplegia, hypoacusis, decreased reﬂexes,
and mild gait ataxia. This patient had depressive mood,
anxiety, moderate cognitive dysfunction, and alcohol
abuse. His brother, mother, and maternal uncle who also
suffered from external ophthalmoplegia had the same
mutation. Genotyping of additional intragenic SNPs re-
vealed that families 1 and 2 do not share a common disease
haplotype and that themutations therefore arose from two
separate events in the two families. No RRM2B mutations
were identiﬁed in ﬁve other unrelated adPEO patients
that we tested.
DNA replication and repair require a balanced supply of
deoxynucleoside triphosphates (dNTPs). In all cells, thecan Journal of Human Genetics 85, 290–295, August 14, 2009 291
Figure 2. Analyses of Patient Muscle
Biopsy for Mitochondrial Respiratory
Chain Activity and mtDNA Quality and
Quantity
(A) Histochemical staining of frozen
muscle section of a patient (family 1,
IV:6) for cytochrome c oxidase (brown)
and succinate dehydrogenase (blue)
reveals abnormal mitochondrial respira-
tory chain activities, as indicated by
arrows. Approximately 10% of the muscle
ﬁbers are affected.
(B) Long-PCR analysis shows multiple
mtDNA deletions in a muscle sample
from an adPEO patient (family 1, IV:6).
An 8.3 kb fragment of mtDNA was ampli-
ﬁed. Similar multiple deletions are present
in the muscle of adPEO patients that have
a mutation in RRM2B, POLG, or C10ORF2,
but not in a control sample.
(C) mtDNA copy number is normal in
muscle samples of adPEO patients (family
1, IV:6, IV:7, IV:8) as determined by quan-
titative real-time PCR as the ratio of the
mitochondrial MT-CYB gene to the
nuclear APP gene. Values are shown rela-
tive to the average of all control samples.
The results were similar when the gene
encoding mitochondrial 12S RNA was
analyzed instead of MT-CYB.
(D) mtDNA point mutation load is normal
in a muscle sample of a patient (family 1,
IV:6) as compared to the control range38
in both the control region of mtDNA and
the MT-CYB gene.major supply of dNTPs comes from the de novo reduction
of ribonucleoside diphosphates to deoxyribonucleoside
diphosphates by the cytoplasmic enzyme ribonucleotide
reductase (RNR).20 In cycling cells, RNR is a heterodimeric
tetramer that consists of R1 and R2 subunits. In postmi-
totic cells, mitochondria are partially supplied for dNTPs
by their own deoxyribonucleotide salvage pathway, but
nuclear DNA repair and mtDNA replication also require
the nucleosides produced by the RNR tetramer, which is
composed of R1 and p53R2 subunits.21–24 RRM2B encodes
p53R2. The p53-inducible subunit p53R2 was initially re-
ported to contribute to nuclear DNA damage response,25,26
and its candidacy for tumor suppression has been evalu-
ated in several mutational analyses of different cancer
types.27–29 However, the contribution of p53R2 to the
DNA damage response has been questioned because its
transcriptional induction upon DNA damage is not rapid
enough for prompt DNA repair.20,26 Instead, ATM-medi-
ated phosphorylation has been suggested to regulate the
DNA repair activity of p53R2 posttranslationally.30 Despite
the unclear role of p53R2 in nuclear DNA repair, it is
certainly essential for the maintenance of mtDNA copy
number in differentiated cells by reducing ribonucleotides
in the cytoplasm:24 homozygous loss-of-function muta-
tions in RRM2B are a cause of severe mtDNA depletion
syndrome (MDS) in infants,19 and Rrm2b knockout mice
die after weaning and present with reduced mtDNA copy
number.19,31 We studied whether the mtDNA copy292 The American Journal of Human Genetics 85, 290–295, August 1number was affected in the skeletal muscle of adPEO
patients of family 1 (IV:6, IV:7, and IV:8) by using real-
time qPCR with TaqMan probes for a portion of the mito-
chondrial MT-CYB gene and the nuclear APP gene as
described14 and found that the mtDNA level in the skeletal
muscle of three patients of family 1 was comparable to the
postmortem samples of control individuals of 19–65 years
of age (Figure 2C).
Some of the RRM2B mutations underlying MDS lead to
early stop codons,19,32 suggesting that the heterozygous
mutation carriers could have both wild-type and truncated
p53R2 protein. However, previously reported western anal-
ysis of tissues from an MDS patient homozygous for a
Q284X mutation showed no protein, suggesting that the
mutated mRNA was subject to nonsense-mediated decay.19
Therefore, haploinsufﬁciency of RRM2B is most likely not
pathological because the heterozygous mutation carriers,
i.e., the parents of the MDS patients, have been reported to
behealthy.19 In our patients, theR327Xnonsensemutation
predicted a truncated protein of 326 amino acids lacking the
25 most C-terminal, highly conserved amino acids. We
cultured myoblasts of one of the patients in family 1 (IV:7)
and studied the presence of the mutation at the RNA level
(Figure 3C). The sequencing of the PCR product revealed
that the c.979C/T mutation was present in the patient’s
RRM2B cDNA and that the mutant transcript thus escaped
nonsense-mediated decay. Nonsense mutations in the
last exon of a gene can escape nonsense-mediated decay4, 2009
because this process usually requires the presence of an
exon-intron junction downstream of the mutation. We
then studied whether the mutant protein was present in
the patient cells by western blot and p53R2 antibody
(Figure 3D). We identiﬁed a truncated variant of p53R2 in
the patient sample in addition to the full-length p53R2
protein, showing that the mutant protein was stable. This
Figure 3. Gene Sequence Analysis of RRM2B and Protein
Analysis of p53R2
(A) Partial DNA sequence of normal RRM2B gene.
(B) Partial DNA sequence of patient’s RRM2B gene showing the
heterozygous c.979C/T mutation.
(C) RRM2B cDNA of patient (family 1, IV:7) myoblasts also
contains the heterozygous c.979C/T mutation. We extracted
total RNA from the cells with an RNeasy kit (QIAGEN). The RNA
was used to generate cDNA with random primers and M-MLV
Reverse Transcriptase (Promega) followed by ampliﬁcation of
part of the RRM2B cDNA with primers listed in Table S1 and Phu-
sion polymerase (Finnzymes).
(D) Western analysis of the p53R2 protein in myoblasts shows
a truncated p53R2 protein present only in the patient sample
(Pt) and not in the control samples (1–3). Ten micrograms of total
cellular protein lysate was analyzed by western blot with p53R2
antibody (ab8105 rabbit polyclonal, Abcam). Actin was used as
a loading control (sc-1616 goat polyclonal, Santa Cruz Biotech-
nology).
(E) The C-terminal amino acids of the p53R2 protein are highly
conserved. The R327 residue is indicated by an arrow, and the
heptapeptide is underlined.The Amersuggested that the mutant protein can compete with the
wild-type in binding to the heterodimeric RNR.
The C terminus of the small subunit of RNR is believed to
be required for the interaction between the homodimers of
R1 and the small subunit (R2 or p53R2) in the heterote-
tramer that represents the active form of the enzyme.
However, the precise manner of interaction is not known
because the C terminus of the small subunit is not visible
in the crystal structures of RNR. The truncated p53R2
protein lacking the C-terminal 25 amino acids is thus pre-
dicted to affect the interaction of the p53R2 dimer with the
R1 dimer because the heptapeptide needed for the interac-
tion is missing33,34 (Figure 3E). Because the mutant protein
causes a dominant trait, it is likely to compete with the
wild-type p53R2 in binding the heterotetramer, leading
to a gain-of-function (competitive binding of mutant
p53R2 altering the function of the heterotetramer) or
a dominant-negative effect (competitive binding inactivat-
ing the heterotetramer) on RNR function. Both models ﬁt
with the fact that the dysfunction is fairly subtle and
that the outcome is adult-onset and muscle-restricted
mtDNA deletions instead of the fatal multisystem mtDNA
depletion that is caused by recessive RRM2B mutations.
Alterations in nucleotide pools can cause increased
mutagenesis.35,36 We also determined the mtDNA point
mutation load in the skeletal muscle of an adPEO patient
(family 1, IV:6) as described37,38 but did not identify
increased numbers of mtDNA point mutations (Figure 2D).
The muscle mtDNA of this patient (age 36 years) had accu-
mulated 0.96 point mutations per 10 kb in the control
region of mtDNA and 0.34 mutations per 10 kb in the
MT-CYB gene region. Approximately 30,000 nucleotides
per mtDNA region were sequenced. Previous studies have
shown that this mutation load is in the same range as
that of the skeletal muscle of healthy control individuals
(~0.2–2 mutations per 10 kb in the control region and
~0.2–1 mutations per 10 kb in theMT-CYB gene region).38
The R327X variant of p53R2 thus does not cause excessive
accumulation of mtDNA point mutations but instead
results in multiple mtDNA deletions. Our patients had
no history of tumors, suggesting that RNR mutations are
not involved in nuclear mutagenesis and induction of
malignancies. Multiple mtDNA deletions in adPEO that
are caused by defects in ANT1 are also thought to result
from unbalanced dNTP pools. Furthermore, multiple dele-
tions are also found in patients with mitochondrial neuro-
gastrointestinal encephalomyopathy (MNGIE), which is
caused by homozygous mutations in the TYMP gene en-
coding cytoplasmic thymidine phosphorylase (TP) that
result in an excess of thymidine and deoxyuridine.39 Our
results show that dominant defects in proteins involved
in dNTP pool regulation are candidates for adult-onset
mitochondrial myopathies.
In conclusion, we have identiﬁed a nonsense mutation
in RRM2B as a cause of autosomal-dominant progressive
external ophthalmoplegia. Our study shows that a defect
in p53R2 can induce a mild muscle disease of adult onsetican Journal of Human Genetics 85, 290–295, August 14, 2009 293
through disturbance of mitochondrial homeostasis but
that this defect does not appear to be oncogenic. Our
ﬁnding extends the list of genes that can cause both domi-
nant PEO and recessive MDS when mutated and suggests
that other MDS genes should be considered for mutation
analysis in patients with multiple mtDNA deletions. The
mechanism of mtDNA deletion formation that is caused
by a dominant-negative or gain-of-function alteration of
truncated p53R2 remains to be determined.
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